Impact of Iron Overload on the Incidence of Liver Complications in Long-Term Survivors (≥10 Years) of Allogeneic Hematopoietic Stem-Cell Transplantation.
Launched by ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS · Jun 11, 2025
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This study is looking at whether having too much iron in the body—a condition called iron overload—affects the chances of developing liver problems in people who had a special type of stem cell transplant called an allogeneic hematopoietic stem cell transplant (HSCT) at least 10 years ago. The researchers will review the health records of about 400 to 500 adults who had their transplant at Hôpital Saint Louis between 2004 and 2014. They will also do some simple tests during a scheduled visit, like blood tests and a painless scan to check how stiff the liver is, which helps show liver health. The main goal is to find out if iron overload leads to more liver issues over the long term, and the study will also look at other factors that might increase risk and how well treatments to reduce iron have worked in the past.
People who might join the study are adults (18 years or older) who had their transplant at Hôpital Saint Louis during the specified years, are still alive and regularly attending follow-up visits, and have health insurance. Participants will be asked to share their medical history and undergo some routine lab tests and liver scans during one visit. This research could help doctors understand if monitoring and treating iron overload early might prevent liver problems many years after transplant, potentially improving long-term health for survivors.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age ≥ 18 years at enrollment
- • Allogeneic HSCT performed at Hôpital Saint Louis between 2004/01/01 and 2014/12/31
- • Alive and attending routine annual follow up within the two years of the study
- • Having given his non-opposition to study after understand overall aims
- • With health insurance coverage
- • Follow up consultation at Saint-Louis Hospital
- Exclusion Criteria:
- • Patient under legal protection (protection of the court, or in curatorship or guardianship).
- • not in relapse of the hematological disease at the time of inclusion.
- • • Patients under 45 Kg
About Assistance Publique Hôpitaux De Paris
Assistance Publique - Hôpitaux de Paris (AP-HP) is a leading public hospital system in France, renowned for its commitment to healthcare excellence and innovative medical research. As a prominent clinical trial sponsor, AP-HP plays a pivotal role in advancing medical knowledge and improving patient care through rigorous scientific investigations across a wide range of therapeutic areas. With a focus on collaboration and interdisciplinary approaches, AP-HP leverages its extensive network of hospitals and expert clinicians to facilitate high-quality clinical trials that adhere to the highest ethical and regulatory standards, ultimately aiming to translate research findings into tangible health benefits for diverse patient populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported